Table I.
Characteristics of the 26 CRPC patients.
| Characteristic | Value |
|---|---|
| Age, years | |
| Mean ± SD | 73.19±9.93 |
| Range | 54.00–88.00 |
| Cycles, n | |
| Median ± SD | 6.92±3.03 |
| Range | 2.00–14.00 |
| Serum PSA, ng/ml | |
| Mean ± SD | 335.58±501.87 |
| Range | 14.67–2363.56 |
| Hemoglobin, g/dl | |
| Mean ± SD | 10.70±1.69 |
| Range | 7.50–13.70 |
| Concomitant estramustine, n (%) | 12 (46) |
| Site of metastasis, n (%) | |
| Bone | 25 (96) |
| Lymph node | 8 (31) |
| Liver | 1 (4) |
| PSA response, n (%) | 15 (58) |
| No PSA decrease, n (%) | 3 (12) |
| PSA nadir, ng/ml | |
| Mean ± SD | 89.97±117.76 |
| Range | 0.84–448.59 |
| Time to PSA nadir, months | |
| Mean ± SD | 4.65±3.60 |
| Range | 0.50–13.00 |
| Time to progression, months | |
| Mean ± SD | 6.50±5.85 |
| Range | 0.00–23.00 |
| Survival time following chemotherapy, months | |
| Mean ± SD | 14.69±10.14 |
| Range | 3–43 |
| Mortality, n (%) | 20 (77) |
| Side-effect, n (%) | |
| Leucopenia | 23 (88) |
| Febrile leucopenia | 4 (15) |
PSA, prostate-specific antigen; SD, standard deviation.